Brief: BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO
19/12/2023 13:22
Dec 19 (Reuters) - BioCryst Pharmaceuticals Inc
BCRX.O :
* BIOCRYST ANNOUNCES PUBLICATION OF DATA FROM OPEN-LABEL
EXTENSION
OF THE APEX-2 PIVOTAL TRIAL OF ORLADEYO® (BEROTRALSTAT)
Source text for Eikon: ID:nGNX67xwt9
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026